1 Faculty of Medicine and Medical Sciences, University of Balamand, El-Koura, Lebanon.
2 Faculty of Engineering, Chemical Engineering, University of Balamand, El-Koura, Lebanon.
Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819853241. doi: 10.1177/1533033819853241.
Chronic myeloid leukemia is a myeloproliferative disease where cells of myeloid linage display a t(9;22) chromosomal translocation leading to the formation of the BCR/ABL fusion gene and the continuous activation of tyrosine kinases. This malignancy has a peak incidence at 45 to 85 years, accounting for 15% of all leukemias in adults. Controlling the activity of tyrosine kinase became the main strategy in chronic myeloid leukemia treatment, with imatinib being placed at the forefront of current treatment protocols. New approaches in future anticancer therapy are emerging with nanomedicine being gradually implemented. Setting through a thorough survey of published literature, this review discusses the use of inorganic nanoparticles in chronic myeloid leukemia therapy. After an introduction on the basics of chronic myeloid leukemia, a description of the current treatment modalities of chronic myeloid leukemia and drug-resistance mechanisms is presented. This is followed by a general view on the applications of nanostrategies in medicine and then a detailed breakdown of inorganic nanocarriers and their uses in chronic myeloid leukemia treatment.
慢性髓细胞白血病是一种髓系增生性疾病，其中髓系细胞显示 t(9;22)染色体易位，导致 BCR/ABL 融合基因的形成和酪氨酸激酶的持续激活。这种恶性肿瘤的发病率高峰在 45 至 85 岁之间，占成年人所有白血病的 15%。控制酪氨酸激酶的活性成为慢性髓细胞白血病治疗的主要策略，伊马替尼被置于当前治疗方案的前沿。纳米医学的逐渐实施为未来的抗癌治疗带来了新的方法。本综述通过对已发表文献的全面调查，讨论了无机纳米粒子在慢性髓细胞白血病治疗中的应用。在介绍慢性髓细胞白血病的基础知识后，本文介绍了慢性髓细胞白血病的当前治疗方法和耐药机制。接下来对纳米策略在医学中的应用进行了概述，然后详细介绍了无机纳米载体及其在慢性髓细胞白血病治疗中的应用。
